ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright

ProKidney Corp. (NASDAQ:PROK) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, ProKidney Corp. (NASDAQ:PROK) has a “buy” rating from slightly more than half of the analysts covering the stock. While the price target ranges from $1 to $12, the median price target of $6.50 reflects an upside potential of 152.92%. Among the analysts bullish on the stock is Joseph Pantginis, an analyst at H.C. Wainwright, who assumed coverage on the company with a ‘Buy’ rating and a $12 price target on December 16, according to TheFly. His price target implies about 367% upside from the current price.

With ProKidney Corp. (NASDAQ:PROK) initiating a fresh approach to “postponing progressive kidney dysfunction,” the analyst believes the company’s lead asset, rilparencel, exhibits the potential to redefine how chronic kidney disease is treated.

Likoper/Shutterstock.com

H.C. Wainwright highlighted that rilparencel, an investigational autologous cell therapy for patients living with chronic kidney disease and type 2 diabetes, has already demonstrated promising results across several Phase 1 and 2 trials. This includes meaningful advancements in estimated glomerular filtration rate (eGFR) drops, a positive safety profile, and a slowed progression to dialysis.

With that said, the company’s current Phase 3 PROACT 1 trial, which is totally in line with its Phase 2 design, has been awarded FDA approval for using eGFR slope as a surrogate endpoint. Through an accelerated regulatory approval process, this could also back a Biologics License Application (BLA) filing.

ProKidney Corp. (NASDAQ:PROK) is a North Carolina-based clinical-stage biotechnology company that provides a cell therapy platform for treating various chronic kidney diseases. Incorporated in 2015, the company is committed to “transforming the treatment landscape for chronic kidney disease.”

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.